Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment

Ou, Y. C., & Chen, H. L. (2018). Immunotherapy in Prostate Cancer: Past, Current, and Future. 童綜合醫學雜誌, 12(1), 1-5. https://www.airitilibrary.com/Article/Detail?DocID=20713592-201806-201806280011-201806280011-1-5
Amm, J. E., Patel, N., Freeman, A., & Ching, J. B. A. (2013). Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide. Clinical Medicine Insights: Oncology, (), 235-245. https://doi.org/10.4137/CMO.S11670
Yeh, T. Y. (2016). Study on the Role of Slit1 Protein in Castration Resistant Prostate Cancer Progression [doctoral dissertation, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU201601335
于大雄、朱燦銘（1995）。Recent Advances in Prostate Specific Antigen (PSA) and Prostate Cancer。中華民國泌尿科醫學會雜誌，6(3)，139-146。https://doi.org/10.7024/JUAROC.199509.0139
Patel, J. C., Maughan, B. L., Agarwal, A. M., Batten, J. A., Zhang, T. Y., & Agarwal, N. (2013). Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer. Prostate Cancer, 2013(), 200-211. https://doi.org/10.1155/2013/981684